Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novartis beats Q4 earnings consensus
Novartis beats Q4 earnings consensus as drug sales surge
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts. Fourth-quarter net income,
Novartis: Q4 Earnings Snapshot
BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it had net income of $1.41. Earnings, adjusted for non-recurring costs, came to $1.98 per share.
Novartis Expects Further Profit, Growth After Key Drugs Boost Sales
Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its key drugs.
1h
on MSN
Novartis earnings, tech stocks maintain STOXX 600's record winning streak
By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...
2h
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...
37m
Balanced Caution: Novartis’s Strong Q4 Performance Amidst Growth Uncertainties
J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...
3h
Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
FierceBiotech
5h
Novartis missed the PD-1 boat. Will it catch the bispecific wave?
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
1h
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
The Pharma Letter
2h
Novartis ups sales growth and margins in 2024
Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...
FierceBiotech
3h
Novartis gives up on anti-CD40 antibody to treat Sjögren’s due to ‘benefit/risk profile’
Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s ...
FiercePharma
2d
Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...
MM&M
2d
Novartis taps Hailee Steinfeld, Wanda Sykes for breast cancer Super Bowl ad
In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...
3h
Bernstein Reaffirms Their Buy Rating on Novartis AG (NOVN)
Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Super Bowl
Hailee Steinfeld
Calendar year
Wanda Sykes
breast cancer
Feedback